Beyond diabetes and obesity: GLP ‐1 receptor agonists in disrupting the vicious cycle of metabolic dysfunction and neuroinflammation

Documenti analoghi

• GLP ‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity
  di: Tommaso Bucci, et al.
  Pubblicazione: (2025)
• GLP ‐1 receptor agonists for treating obesity without diabetes: A systematic review and meta‐analysis of economic evaluations
  di: Teerapon Dhippayom, et al.
  Pubblicazione: (2025)
• Cardiovascular and kidney outcomes of GLP ‐1 receptor agonists in adults with obesity: A target trial emulation study
  di: Huilin Tang, et al.
  Pubblicazione: (2025)
• Effectiveness and safety of GLP ‐1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real‐world study
  di: Flora Lambert, et al.
  Pubblicazione: (2025)
• Comparative healthcare resource utilization and costs of empagliflozin and GLP ‐1 receptor agonists in type 2 diabetes
  di: Phyo Than Htoo, et al.
  Pubblicazione: (2025)